We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Prognostic Tool Identified for Newly Diagnosed Multiple Myeloma

By LabMedica International staff writers
Posted on 29 Dec 2016
Print article
Image: A photomicrograph of bone marrow aspirate from a patient with multiple myeloma, showing numerous plasma cells, which can be recognized by the eccentric nucleus and perinuclear halo (Photo courtesy of Dr. Michael G. Bayerl).
Image: A photomicrograph of bone marrow aspirate from a patient with multiple myeloma, showing numerous plasma cells, which can be recognized by the eccentric nucleus and perinuclear halo (Photo courtesy of Dr. Michael G. Bayerl).
The bone marrow (BM) microenvironment contains numerous cell types, including immunosuppressive tumor-associated macrophages (TAM), that promote the growth and survival of multiple myeloma (MM) cells.

Emerging evidence suggests that the absolute monocyte count (AMC) in peripheral blood may reflect the level of TAM recruitment at the tumor site and its prognostic significance has been shown in other lymphoid malignancies. Absolute lymphocyte count (ALC) as a surrogate marker for host immune system has prognostic significance.

A team of scientists led by those at University Hospitals Case Medical Center (Cleveland, OH, USA) investigated the prognostic significance of the ratio of ALC, as a surrogate of host immune status, to AMC, which reflects the MM-immune microenvironment, in predicting clinical outcome among newly diagnosed MM patients. The study included 372 MM patients diagnosed 2004-2014 who had complete blood count (CBC) differentials at diagnosis. The primary end-point of the study was progression free survival (PFS) calculated from the time of diagnosis.

The median patient age was 67.3 years (range: 30-92), 53% were male and 47% female. At the time of this analysis 92 patients (24%) had died, 75 (20%) of them was due MM. The median AMC, ALC and ALC/AMC ratio at diagnosis was 412 cells/µL, 1,461 cells/µL and 3.9, respectively. Neither ALC nor AMC was associated with different PFS or overall survival (OS). ALC/AMC as a continuous variable was identified as a predictor of PFS; hazard ratio (HR) = 0.62.The 236 patients with an ALC/AMC equal to or greater than 3.6 experienced a superior median PFS compared to the 136 patients with an ALC/AMC less than 3.6; Median PFS, 24 versus 43 months respectively. Low ALC, high AMC, and low ALC/AMC ratio were associated with poor prognostic factors such as high β2-microglobulin.

The authors concluded that myeloma patients with a higher ALC/AMC at diagnosis enjoyed a longer PFS (either as a continuous or dichotomized variable). Also, multivariate analysis demonstrated that patient with tumors that harbored del (17p) or t(4, 14) had low ALC/AMC ratio suggesting possible immunoparesis. The data potentially suggest the ALC/AMC ratio as a readily available surrogate marker to assess the relative strength of host immune system to myeloma-induced immunoparesis. The ratio can serve as a biomarker to stratify patients for future immunological therapies an also indicates that the host immune status should be carefully monitored. The study was presented at the 58th Annual Meeting of American Society of Hematology (ASH) held December 3-6, 2016, in San Diego, CA, USA.

Related Links:
University Hospitals Case Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.